Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome

An announcement from Kyverna Therapeutics, Inc. ( (KYTX) ) is now available.

On April 21, 2026, Kyverna reported positive primary analysis results from its registrational Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome, with data presented as a late-breaking oral session at the American Academy of Neurology meeting. A single dose of miv-cel produced rapid, statistically significant and clinically meaningful improvements across all primary and secondary endpoints at 16 weeks, including a 46% median improvement in walking speed, major gains in mobility and disability scores, and complete discontinuation of chronic immunotherapies in all 26 patients.

The therapy showed a well-tolerated safety profile with no high-grade cytokine release syndrome or neurotoxicity and manageable hematologic adverse events, supporting its outpatient potential. Alongside natural history data demonstrating that existing off-label treatments yield minimal functional improvement, the KYSA-8 results highlight miv-cel’s potential to become the first approved treatment for stiff person syndrome and to reshape the treatment paradigm in neurologic autoimmune disease, while also bolstering Kyverna’s broader CAR T pipeline strategy.

The most recent analyst rating on (KYTX) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.

Spark’s Take on KYTX Stock

According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.

The score is held back primarily by weak financial performance—zero recent revenue alongside widening losses and accelerating cash burn—despite a low-debt balance sheet. Offsetting this, the stock shows strong bullish technicals (though overbought) and recent corporate events are positive, highlighted by encouraging Phase 2 durability/safety data and leadership additions.

To see Spark’s full report on KYTX stock, click here.

More about Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. is a late-stage clinical biopharmaceutical company specializing in cell therapies for patients with autoimmune diseases, with a focus on neurologic indications such as stiff person syndrome and generalized myasthenia gravis. The Nasdaq-listed company is advancing its lead CAR T-cell therapy candidate miv-cel (mivocabtagene autoleucel, KYV-101) through registrational trials to address severe, underserved autoimmune conditions.

Average Trading Volume: 728,808

Technical Sentiment Signal: Strong Buy

Current Market Cap: $679.9M

See more insights into KYTX stock on TipRanks’ Stock Analysis page.